Amanta Healthcare Limited has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 11, 2026, was addressed to both BSE Limited and the National Stock Exchange of India Limited.

Board Meeting Details

The meeting of the Board of Directors is scheduled to be held on Tuesday, May 19, 2026. The primary agenda of the meeting is to consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026.

Key details of the board meeting are summarised below:

Trading Window Closure and Reopening

In continuation of an earlier intimation dated March 28, 2026, the company has informed exchanges about the status of the trading window. The trading window was closed from Wednesday, April 01, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. The trading window is set to reopen on Friday, May 22, 2026.

The intimation was signed by Nikhita Dinodia, Company Secretary of Amanta Healthcare Limited, with a digital signature dated May 11, 2026.

Amanta Healthcare Limited has provided a clarification to stock exchanges regarding the completion of a share acquisition transaction by promoter Shri Bhavesh Patel. The company confirmed that the remaining portion of shares from an earlier acquisition has been successfully credited to the promoter's demat account.

Transaction Completion Details

The company clarified that 15,500 equity shares purchased on March 30, 2026, were credited to Shri Bhavesh Patel's demat account on April 17, 2026. This represents the completion of a larger transaction involving 28,800 equity shares, for which the company had provided initial intimation to stock exchanges on April 1, 2026.

The clarification follows an earlier communication dated April 18, 2026, regarding the credit of 13,300 equity shares to the same promoter's demat account, indicating that the transaction was completed in two separate tranches.

Revised Shareholding Position

Following the complete transaction, the company has provided updated details of the promoter's shareholding position:

The acquisition represents a marginal increase of 0.04% in the promoter's voting capital, bringing the total shareholding to 16.29% from the previous 16.25%.

Regulatory Compliance

Amanta Healthcare has requested both BSE Limited and National Stock Exchange of India Limited to take this clarification on record and replace the earlier intimation with the revised information. This ensures accurate reflection of the promoter's shareholding position in the exchange records.

The company's communication, signed by Company Secretary and Compliance Officer Nikhita Dinodia, demonstrates adherence to regulatory disclosure requirements for promoter share transactions. The clarification provides transparency regarding the timing and completion of the share credit process, ensuring all stakeholders have accurate information about the promoter's current shareholding status.